Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Other Comprehensive Income [Abstract]
Net (loss) income	$ (81,678)	$ (10,094)
Less: Net (income) loss attributable to non-controlling interests	(9,965)	3,151
Net loss attributable to Amneal Pharmaceuticals, Inc.	(91,643)	(6,943)
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period	(390)	1,797
Unrealized gain (loss) on cash flow hedge, net of tax of $0	15,543	(14,270)
Reclassification of cash flow hedge to earnings, net of tax of $0	(6,515)	0
Less: Other comprehensive loss attributable to non-controlling interests	0	6,236
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	8,638	(6,237)
Comprehensive loss attributable to Amneal Pharmaceuticals, Inc.	$ (83,005)	$ (13,180)